CSG / BERLIN · PART OF ATHAGORAS GROUP

Data that holds.
Evidence that moves the marker.
We build the arc of evidence.

A Berlin-based Full-Service CRO embedded within the 500+ expert network of the athagoras group. Ten stages, one continuous curve. From your first idea to the moment a regulator says yes and a patient gets better.

25+Years D-A-CH
500+Expert Network
10Stages
1Single Point of Contact
SCROLL
STAGE 01 · STUDY CONCEPT

The foundation of every successful trial.

Strategic goals translated into research questions. A rigorous concept that defines the scientific and regulatory pathway, determines feasibility, and shapes timeline and budget for everything that follows.

Strategy → ready-for-submissionTypical duration
Interdisciplinary: clinicians, biostatisticians, PM, RA, market accessWho leads
01
SCENE 01STUDY CONCEPT
01
STAGE 02 · PROTOCOL DEVELOPMENT

Protocol writing in accordance with EMA and BfArM standards.

Comprehensive protocol, patient information and consent forms, Investigator Brochure, Case Report Forms, IMPD documentation. Medical writing prepared for every reviewer your study will encounter.

Typically 4–10 weeksTypical duration
Senior Medical WriterWho leads
02
PROTOCOL v1.0READY
SCENE 02PROTOCOL DEVELOPMENT
02
STAGE 03 · REGULATORY & ETHICS

BfArM · PEI · EMA

Scientific advice and protocol assistance, Clinical Trial Application filing, and Ethics Committee submissions. Regulatory roadmap mapped from the start, not retrofitted.

6–14 weeksTypical duration
Regulatory Affairs LeadWho leads
03
BfArMPEIEMAFDAG-BAECMDRIVDR
SCENE 03REGULATORY & ETHICS
03
STAGE 04 · PATIENT RECRUITMENT

Clear insight into the hospital landscape.

Feasibility analysis and site identification drawing on our network's site analytics, realistic recruitment timeline estimation, and competitive landscape intelligence. All backed by our D-A-CH CRA network.

6–12 weeks of planning · then liveTypical duration
Project ManagerWho leads
04
D · A · CH
SCENE 04PATIENT RECRUITMENT
04
STAGE 05 · PROJECT MANAGEMENT

Single Point of Contact. Fast-Decision Making.

Our Single Point of Contact (SPOC) model means one dedicated Project Manager serves as your central hub for all study activities, and your first point of contact as sponsor. From your initial briefing through to delivery, one person coordinates all study activities across study sites, service providers, regulatory authorities, and your internal team. Our flat hierarchies streamline bureaucratic processes and lead to quick decisions.

Whole projectTypical duration
Dedicated Project ManagerWho leads
05
SPOCSITESVENDORSREGETHICSSPONSORTEAM
SCENE 05PROJECT MANAGEMENT
05
STAGE 06 · MONITORING

Expert-Led Monitoring. End-to-End.

On-site Source Data Verification, remote EDC review, and Risk-Based Monitoring blended into one strategy. Maximum oversight, optimised resources: effort focused on the risks that actually matter to your endpoints.

Whole studyTypical duration
D-A-CH CRA NetworkWho leads
06
ICH-GCP E6(R3) · RBM · SDV
SCENE 06MONITORING
06
STAGE 07 · DATA MANAGEMENT

Full pipeline. Zero compromise.

From first patient entry to submission-ready delivery: Remote Data Capture via Oracle Clinical RDC, hybrid CRF approaches, integrated ePRO and eDiary, GAMP 5 / 21 CFR Part 11 / Annex 11 / EMA/INS/GCP/112288/2023 / GDPR compliant.

Build 6–10w · Live: whole studyTypical duration
Head of Data ManagementWho leads
07
SUBJIDVISITPARAMVALUES-1000V1HR60.0S-1007V2SBP63.7S-1014V3TEMP67.4S-1021V4BMI71.1S-1028V1HR74.8S-1035V2SBP78.5S-1042V3TEMP82.2
SCENE 07DATA MANAGEMENT
07
STAGE 08 · BIOSTATISTICS

Biostatistics You Can Build On.

CSG Biostatistics delivers validated, CDISC-compliant statistical analyses and programming in SAS® or R, covering everything from study design and SAP authoring to regulatory submission support, tailored to your research objectives.

Whole studyTypical duration
BiostatisticianWho leads
08
SAS® · ICH E9 · CDISC
SCENE 08BIOSTATISTICS
08
STAGE 09 · PHARMACOVIGILANCE

Full vigilance. Zero blind spots.

SAE management, SUSAR reporting, RMP creation and updates, signal detection, DSMB participation. Materiovigilance for MedTech.

Whole study + lifecycleTypical duration
PV ScientistsWho leads
09
PSUR · DSUR · QPPV
SCENE 09PHARMACOVIGILANCE
09
STAGE 10 · REAL-WORLD EVIDENCE

When market approval is the beginning.

NIS, PASS, PAES, PMS, label updates. RWE strategy, registries, AbD (§35a SGB V), Erprobungsstudien (§137e SGB V). Health Care Research · Patient Preferences · Clinical Pathways.

Lifecycle horizonTypical duration
RWE LeadWho leads
10
NISPASSPMSAbD§137eSmartCareRWE
SCENE 10REAL-WORLD EVIDENCE
10
WHY CSG

Small enough to be agile.
Rooted deep enough to matter.
Large enough to handle anything.

01 / SPOC

Single Point of Contact

One dedicated PM for every project. No fragmentation, no delays.

02 / FLEXIBLE

Full-Service or FSP

Engagement tailored to your needs, from a single workstream to a whole study.

03 / REGULATORY

Regulatory Expertise

BfArM · PEI · EMA · FDA · G-BA · MDR: fluent in every dialect.

04 / CRO

CRO Expertise

Phase II–IV · CE-Mark · §137e · DiGA · AbD · RWD: the full evidence stack.

05 / QUALITY

Quality First

ICH-GCP E6(R3) · MDR · GDPR compliant

25+Years D-A-CH Experience
500+Expert Network · athagoras group
1–90Sites · from boutique to nationwide
START THE CONVERSATION

Ready to sketch
the arc of your trial?

Lots of engagements start with a 30-minute call. By the end of it you'll have a feasibility view, a regulatory roadmap, and a named PM.

Start the conversation →